13-valent pneumococcal vaccine clinical trials
Also written PCV13.
How each study uses 13-valent pneumococcal vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 13-valent pneumococcal vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Feb 2010 · Prevnar 13 · BLA 125324 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
128 studies that test it; most in 2007 (15)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 6 |
| 2007 | 15 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 8 |
| 2011 | 5 |
| 2012 | 9 |
| 2013 | 15 |
| 2014 | 9 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 7 |
| 2018 | 12 |
| 2019 | 7 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 73 · Other 56
Pfizer (35) · Wyeth is now a wholly owned subsidiary of Pfizer (22) · GlaxoSmithKline (6) · University of Oxford (5) · Korea University Guro Hospital (4) · Sanofi Pasteur, a Sanofi Company (3) · Assistance Publique - Hôpitaux de Paris (2) · Helsinki University Central Hospital (2)
Often tested with
Tested in the same studies.
23-valent pneumococcal capsular polysaccharide vaccine (8) · Pneumococcal Vaccines (7) · 10-valent pneumococcal conjugate vaccine (4) · Meningococcal Vaccines (3) · Pneumococcal 20-Valent Conjugate Vaccine (2) · Influenza Vaccines (2) · Hepatitis A Vaccines (2) · PHiD-CV vaccine (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
13-valent pneumococcal vaccine is the comparator. A study of two new drugs counts under both.
- 1Pneumococcal 20-Valent Conjugate Vaccine · Pfizer · next primary completion Nov 2028
Reaching primary completion within a year · 1
Studies that test 13-valent pneumococcal vaccine.
- May 2027Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsPhase 1/2 · Sanofi Pasteur, a Sanofi Company
Studies
Open first, then newest update. How each study uses 13-valent pneumococcal vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 129
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a LymphomaRecruitingPhase 4Poitiers University HospitalNCT04460235Written as Prevenar 13 + Pneumovax 23
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsRecruitingPhase 2GlaxoSmithKlineNCT07286370Written as Prevenar 13
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT05412030Written as Prevnar 13
- Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in IndiaCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00452790Written as 13-valent Pneumococcal Conjugate Vaccine
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 YearsCompletedPhase 1Reinovax Biologics Co., LTDNCT06675032Written as 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Impact of HIV-1 and Aging on Mucosal Vaccine ResponsesActive, not recruitingEarly Phase 1VA Eastern Colorado Health Care SystemNCT03729778Written as Prevnar-13
- Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 YearsCompletedPhase 3PfizerNCT00761631Written as 13 valent pneumococcal conjugate vaccine
- Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.CompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03873727Written as Prevenar13 (PCV13) and Pneumovax (PPS23)
- A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthCompletedPhase 1/2Janssen Research & Development, LLCNCT03819049Written as Prevnar 13
- A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In ChinaCompletedPhase 3PfizerNCT01692886Written as 13-valent Pnumococcal Conjugate vaccine
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsCompletedPhase 1PfizerNCT07019909Written as 13vPnC
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06647407Written as Pneumococcal 13-valent conjugate vaccine
- Genomics and Epigenomics of the Elderly Response to Pneumococcal VaccinesCompletedPhase 4The Jackson LaboratoryNCT03104075Written as Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein
- Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)Active, not recruitingNot applicableUniversity of California, Los AngelesNCT01527591Written as Pneumococcal Conjugate Vaccine 13 (PCV13)
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedPhase 4Emory UniversityNCT04080531Written as Pneumococcal 13-valent Conjugate Vaccine
- PCV13 + Hepatitis a Vaccine for AdultsCompletedPhase 4Helsinki University Central HospitalNCT01926860Written as Prevenar13
- Fever After Simultaneous Versus Sequential Vaccination in Young ChildrenCompletedPhase 4Duke UniversityNCT03165981Written as PCV13
- The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan InfantsCompletedPhase 4London School of Hygiene and Tropical MedicineNCT03489018Written as PCV13
- A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young ChildrenCompletedPhase 3PfizerNCT03574389Written as 13vPnC
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03691610Written as Pneumococcal 13-valent Conjugate Vaccine
See all 129 studies that test 13-valent pneumococcal vaccine →
Given beside what is tested · 55 — 13-valent pneumococcal vaccine is usual care or a partner of the new treatment
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingPhase 1/2Mayo ClinicNCT03942328Written as Pneumococcal 13-valent Conjugate Vaccine
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as PREVNAR 13
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06740630Written as PCV (pneumococcal conjugate vaccine) 13
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06693895Written as PCV (pneumococcal conjugate vaccine) 13
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06806137Written as PCV (pneumococcal conjugate vaccine) 13
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06855160Written as PCV (pneumococcal conjugate vaccine) 13
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as Prevnar13
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 MonthsCompletedPhase 2Reinovax Biologics Co., LTDNCT07333352Written as 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)
- Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedPhase 1/2Mayo ClinicNCT03035331Written as Pneumococcal 13-valent Conjugate Vaccine
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedPhase 2Jennifer WoyachNCT02518555Written as Pneumococcal 13-valent Conjugate Vaccine
- Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate VaccineCompletedPhase 1/2Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06703203Written as 13-Valent pneumococcal conjugate vaccine
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT05794230Written as Pneumoccocal Vaccine
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03069703Written as PCV13
- Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete RemissionTerminatedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03376477Written as Prevnar13
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT05084508Written as 13-valent pneumococcal conjugate vaccine
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and TaiwanCompletedPhase 3PfizerNCT04875533Written as 13vPnC
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03537508Written as Pneumococcal 13-valent conjugate vaccine
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and ToddlersCompletedPhase 4GlaxoSmithKlineNCT04535037Written as Pneumococcal 13-valent conjugate vaccine
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03673462Written as Pneumococcal 13-valent Conjugate Vaccine
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03632720Written as Pneumococcal 13-valent polysaccharide conjugate vaccine
Showing 20 of 55.
As the comparator · 65 — what is tested is compared with 13-valent pneumococcal vaccine
- A Study to Evaluate 20vPnC in Healthy Chinese InfantsRecruitingPhase 3PfizerNCT07754539Written as 13vPnC
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)RecruitingPhase 1/2CanSino Biologics Inc.NCT07600983Written as PCV13 vaccine
- Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)Not yet recruitingPhase 3Sinovac Life Sciences Co., Ltd.NCT07593924Written as Prevenar 13™
- A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60Not yet recruitingPhase 1Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06970756Written as 13-valent Pneumococcal Conjugate Vaccine
- Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy VolunteersNot yet recruitingPhase 3Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT04357522Written as 13-Valent Pneumococcal Conjugate Vaccine
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantActive, not recruitingPhase 1PfizerNCT07023081Written as 13vPnC
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Active, not recruitingPhase 3CanSino Biologics Inc.NCT07017777Written as Prevnar 13
- Clinical Trial of PCV24 in Children Aged 2-17 YearsCompletedPhase 1Sinovac Life Sciences Co., Ltd.NCT06550830Written as Prevenar13®
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedPhase 1Sinovac Research and Development Co., Ltd.NCT06183216Written as PREVNAR 13
- A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwanCompletedPhase 3PfizerNCT05512819Written as 13-valent pneumococcal conjugate vaccine
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT04398706Written as Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)CompletedPhase 1Merck Sharp & Dohme LLCNCT03848065Written as Pneumococcal 13-valent Conjugate Vaccine (PCV13)
- Extension Safety and Immunogenicity Study of GPNV-001CompletedPhase 1/2GPN VaccinesNCT05982314Written as Prevenar-13
- Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)CompletedPhase 1Sanofi Pasteur, a Sanofi CompanyNCT06698198Written as Prevnar 13®
- Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in InfantsActive, not recruitingPhase 3Fosun Adgenvax Biopharmaceutical Co.,Ltd.NCT05759520Written as Prevenar 13
- Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13CompletedPhase 3PfizerNCT05408429Written as 13-valent pneumococcal conjugate vaccine
- Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.CompletedPhase 1GPN VaccinesNCT05667740Written as Prevenar-13
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of AgeCompletedPhase 1PfizerNCT05489328Written as 13vPnC
- Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)CompletedPhase 3CanSino Biologics Inc.NCT04841369Written as 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy InfantsCompletedPhase 3PfizerNCT04546425Written as 13-valent pneumococcal conjugate vaccine
Showing 20 of 65.